Adaptive Biotechnologies (ADPT) stock soared to a three-year high, reaching $18.98 before closing at $18.61, up 14.03% on Friday. The surge followed the Jefferies London Healthcare Conference where ADPT announced operational updates, expecting $20 million in pharmaceutical services revenue and over 50% increase in EMR integrated testing volumes. ADPT also anticipates participating in the upcoming Piper Sandler Healthcare Conference on December 3. In Q3, ADPT swung to a $9.5 million net income from a $32.07 million loss last year. Revenues grew 102% to $93.97 million, including $33.7 million from Immune Medicine following the termination of the Genentech Agreement.

Read more at Yahoo Finance: Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here’s Why